Search filters

Authors whose works are in public domain in at least one jurisdiction

List of works by Christoph Driessen

A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis

scientific article published on 21 February 2019

Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.

scientific article

An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when

scholarly article by Jo Caers et al published 31 August 2018 in Haematologica

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors

scientific article published on 01 October 2018

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer

article

Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.

scientific article

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.

scientific article published on 5 July 2017

Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic proteinin vitro ⬇️

scientific article published on December 1, 2001

Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells

scientific article

Development of new Malt1 inhibitors and probes.

scientific article

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

scientific article published on 20 May 2016

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

scientific article published on February 2014

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors

scientific article published on 07 December 2018

Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.

scientific article published on 21 November 2017

Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma

scientific article published on 01 November 2019

Management of cardiovascular risk in patients with multiple myeloma

scientific article published on 26 February 2019

Multiple myeloma: practice patterns across Europe

scientific article

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10) ⬇️

scientific article published on 27 August 2019

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance ⬇️

scientific article published on March 1, 2013

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events ⬇️

scientific article published on May 1, 2011

Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma

scientific article published on 04 April 2019

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

scientific article published on 12 August 2011

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

scientific article published on 25 April 2016

Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC

scientific article published on 19 November 2019

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

scientific article published on 2 May 2018

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension

scientific article published on 08 April 2019

Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer

scientific article published on 25 January 2019

Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma

scientific article published on 01 April 2019

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma

scientific article published on 20 September 2018

Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

scientific article published on 03 January 2019

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

scientific article published on 27 April 2016

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

scientific article published on 19 August 2020

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma

scientific article published on 18 February 2019

Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations

scientific article published on 25 December 2013

Spectrum and functional validation of PSMB5 mutations in multiple myeloma

scientific article published on 19 July 2018

Spotlight on pomalidomide: could less be more?

scientific article published on 22 May 2017

Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits

scientific article published on 05 February 2019

Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab

scientific article published on 03 August 2018

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.

scientific article published on 28 July 2017

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma

scientific article

Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland

scientific article published on 01 March 2019

Paulina is supported by:

About Paulina

Help